New and Future Drug Development for Gastroesophageal Reflux Disease.
- Author:
Carla MARADEY-ROMERO
1
;
Ronnie FASS
Author Information
1. The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. ronnie.fass@gmail.com
- Publication Type:Review
- Keywords:
Erosive esophagitis;
Gastroesophageal reflux;
Heartburn;
Proton pump inhibitors
- MeSH:
Esophageal Sphincter, Lower;
Gastroesophageal Reflux*;
Heartburn;
Histamine;
Proton Pump Inhibitors;
Proton Pumps;
Relaxation
- From:Journal of Neurogastroenterology and Motility
2014;20(1):6-16
- CountryRepublic of Korea
- Language:English
-
Abstract:
Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.
